Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivim Health vs Obu Health

Ivim Health
Graded #338

Lower grade

vs+0.29999999999999716
Obu Health
Graded #332

Higher grade

The verdict

Obu Health takes it — 59.9/100 to 59.6/100, but only just.

Obu Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons. Ivim Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
44
44
Dose & formulationEven
64
64
Clinical oversightObu Health +5
79
84
Labs & monitoringObu Health +1
52
53
FulfillmentObu Health +9
65
74
Contract termsIvim Health +24
55
31
Ivim Health · left barObu Health · right bar

The numbers

MetricIvim HealthObu Health
WeighScore59.6/10059.9/100
GradeCC
Scorecard rank#338#332
Semaglutide$149/mo (starting dose, medication and programme fee, compounded)$190/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$224/mo (starting dose, medication and programme fee, compounded)$239/mo (starting dose, plus a separate fee, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ivim Health

Graded #338 · C

Strengths

  • Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
  • A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
  • The first month of the membership is free

Where it loses points

  • A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
  • The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
  • Both figures are 'starting at' rates, so the cost of a titrated dose is not published
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard